tenofovir/emtricitabine/rilpivirine

DRUG2 trials

Sponsors

St Stephens Aids Trust, Mahidol University

Conditions

Anti-Retroviral AgentsDyslipidemiasEfavirenzHIVHIV-1-infectionRilpivirineSustained Virologic Response

Phase 3

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

CompletedNCT01701882

St Stephens Aids TrustHIV

Start: 2012-09-30End: 2013-11-30Updated: 2017-07-26

Unknown Phase

Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression

CompletedNCT03251690

Mahidol UniversityAnti-Retroviral Agents, Dyslipidemias, Efavirenz +3

Start: 2016-10-27End: 2018-04-30Updated: 2019-05-07